The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug Administration (FDA) as the first prescription drug to help alleviate moderate-to-severe obstructive sleep apnea (OSA) for adults with obesity.
Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound ...
The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication ...
Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli Lilly drug initially developed as a ...
Eli Lilly expects to launch the drug for OSA at ... The index is used to evaluate the severity of obstructive sleep apnea and the effectiveness of treatments for the condition.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback